Immatics N.V..
IMTX.US | Manufacture of pharmaceuticals, medicinal chemical and botanical products
Immatics N.V. is a clinical-stage biopharmaceutical company focused on the discovery and development of T cell redirecting immunotherapies for the treatment of cancer. The company's pipeline includes adoptive cell therapies and bispecifics, designed to target cancer cells by redirecting the patient'...Show More
Better Health for All
-30
Immatics N.V. is entirely devoted to developing cancer immunotherapies, with its products aiming to deliver exceptional health benefits for patients with unmet medical needs. Its IMA203 PRAME cell therapy showed a confirmed Objective Response Rate (cORR) of 56% and a median Overall Survival (mOS) of 15.9 months in melanoma patients.
1
The company's R&D expenses were $55.4 million for the three months ended September 30, 2025,
2
representing 908% of its $6.1 million revenue for the same period,
3
indicating significant investment in health innovation. The company maintains a strong commitment to ethical clinical trials, conducting them in compliance with GCP, GMP, GLP, GDP, and GVP,
4
and emphasizes patient best interest and accurate information.
5
However, the company's products, while beneficial, have a notable safety profile, with 11% of patients experiencing Grade 3 Cytokine Release Syndrome (CRS)
6
and 4% experiencing Grade 3 Immune effector cell-associated neurotoxicity syndrome (ICANS) in IMA203 trials.
7
The company's risk transparency is moderate, with general statements about forward-looking risks and preliminary data,
8
but no specific public health information resources. While trials include heavily pretreated patients,
9
there is no explicit evidence of programs to reach low-income or marginalized populations, only that trials are planned for North America and Europe.
10
The company adheres to data privacy laws like GDPR and US legislation,
11
but specific details on transparency and user control are limited.
Fair Money & Economic Opportunity
0
No evidence available to assess Immatics N.V. on Fair Money & Economic Opportunity.
Fair Pay & Worker Respect
-20
The company's overall employee engagement and satisfaction rating is 2.7 out of 5 stars, based on 10 reviews.
1
Employee reviews indicate concerns regarding pay, a lack of raises and promotions, job security, and limited advancement opportunities.
2
Multiple reviews also mention high turnover and criticize senior management for avoiding issues and a lack of support.
3
Benefits are described as 'average,' including 4 weeks of PTO and a 401k match starting at 3%.
4
Fair Trade & Ethical Sourcing
0
No specific, concrete data points or facts regarding Immatics N.V.'s fair trade and ethical sourcing practices were found in the provided articles.
1
There is no evidence related to fair-trade certification, supplier audit frequency, forced or child labor incidents, supply chain traceability, remediation speed for violations, ethical clause coverage in supplier contracts, materials risk, or supplier diversity spend.
2
Honest & Fair Business
-40
Immatics N.V. has a formal whistleblower policy that includes a confidential and anonymous hotline for financial concerns, accessible via phone and web form.
1
This facility is a requirement by the SEC.
2
However, there is no evidence regarding independent investigation processes, training, or the effectiveness of the policy.
Kind to Animals
0
No specific information regarding Immatics N.V.'s animal welfare practices, animal testing policies, volume of animals used, investment in animal-free alternatives, or any related certifications or conservation efforts was found in the provided articles.
1
While one article mentions the company's Audit Committee supervises the integrity and quality of its sustainability reporting, no details from such reporting relevant to animal welfare KPIs were provided.
2
No War, No Weapons
0
Immatics N.V. is consistently described as a clinical-stage biopharmaceutical company focused on developing T cell redirecting immunotherapies for cancer treatment.
1
The company's stated use of proceeds from offerings is to fund research and development, manufacturing, production, and commercialization of product candidates, as well as for working capital and general corporate purposes.
2
There is no evidence in any of the provided articles to suggest involvement in arms manufacturing, military contracts, dual-use technology with military applications, sales to embargoed regimes, or any other activities related to war or weapons. Therefore, all KPIs are scored as '0' (N/A) as these activities are not part of the company's core business or operations.
Planet-Friendly Business
0
No specific, scorable evidence for any of the 'Planet-Friendly Business' KPIs was found in the provided articles for Immatics N.V.
1
The articles primarily focus on financial results, clinical trial updates, and general business conduct, without providing concrete data on environmental performance, targets, or initiatives.
2
Information related to Immedica Pharma UK Ltd's carbon reduction plan is not applicable to Immatics N.V. as no explicit link or subsidiary relationship is stated.
3
Respect for Cultures & Communities
0
No information regarding Immatics N.V.'s respect for cultures and communities, including formal partnerships, community investments, cultural incident records, or local employment, was found in the provided articles.
1
The articles primarily focus on the company's expanded access policy and corporate governance structure, explicitly stating they do not contain data relevant to the requested metrics.
2
Safe & Smart Tech
0
Immatics N.V. uses 256-bit TLS encryption for data transfer between user computers and its server.
1
The company explicitly states compliance with the European Union General Data Protection Regulation (GDPR) and all applicable US data privacy legislation.
2
It has a policy to delete data when the purpose of storage no longer exists, subject to legal retention obligations which can range from three to ten years.
3
Users are granted rights to access, rectify, erase, restrict processing, and object to data processing, consistent with GDPR requirements.
4
Zero Waste & Sustainable Products
0
No specific data or concrete facts were found in the provided articles regarding Immatics N.V.'s performance on waste diversion rates, product recyclability, packaging sustainability, recycled content, single-use plastic reduction, take-back programs, circular design principles, waste reduction initiatives, hazardous waste management, product durability, repairability, waste audit frequency, zero waste certification, waste disposal violations, material efficiency, packaging to product ratio, waste reduction targets, supplier waste requirements, or customer waste education.
1
The articles explicitly state the absence of relevant environmental sustainability metrics, focusing instead on corporate culture, employee values, financial performance, and general company operations.
2